参考文献/References:
[1] Dass K, Ahmad A, Azmi AS, et al.Evolving role of uPA/uPAR system in human cancers[J].Cancer Treat Rev, 2008, 34(2):122-136.DOI:10.1016/j.ctrv.2007.10.005.
[2] Noh H, Hong S, Huang S.Role of urokinase receptor in tumor progression and development[J].Theranostics, 2013, 3(7):487-495.DOI:10.7150/thno.4218.
[3] Dohn LH, Pappot H, Iversen BR, et al.uPAR expression pattern in patients with urothelial carcinoma of the Bladder-Possible clinical implications[J/OL].PLoS One, 2015, 10(8):e0135824[2016-01-05].http://www.ncbi.nlm.nih.gov/pubmed/26292086.DOI:10.1371/journal.pone.0135824.
[4] Smith HW, Marshall CJ.Regulation of cell signalling by uPAR[J].Nat Rev Mol Cell Biol, 2010, 11(1):23-36.DOI:10.1038/nrm2821.
[5] Yang J, Duh EJ, Caldwell RB, et al.Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression[J].Invest Ophthalmol Vis Sci, 2010, 51(6):3273-3280.DOI:10.1167/iovs.08-2878.
[6] Messaritou G, East L, Roghi C, et al.Membrane type-1 matrix metalloproteinase activity is regulated by the endocytic collagen receptor Endo180[J].J Cell Sci, 2009, 122(Pt 22):4042-4048.DOI:10.1242/jcs.044305.
[7] Czekay RP, Loskutoff DJ.Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism[J].J Cell Physiol, 2009, 220(3):655-663.DOI:10.1002/jcp.21806.
[8] Baldini E, Sorrenti S, D’Armiento E, et al.The urokinase plasminogen activating system in thyroid cancer:clinical implications[J].G Chir, 2012, 33(10):305-310.
[9] Gonias SL, Hu J.Urokinase receptor and resistance to targeted anticancer agents[J/OL].Front Pharmacol, 2015, 6:154[2016-01-05].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515545/.DOI:10.3389/fphar.2015.00154.
[10] Nalla AK, Gorantla B, Gondi CS, et al.Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells[J].Cancer Gene Ther, 2010, 17(9):599-613.DOI:10.1038/cgt.2010.16.
[11] Chetty C, Lakka SS, Bhoopathi P, et al.Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells[J].Mol Cancer Ther, 2010, 9(9):2605-2617.DOI:10.1158/1535-7163.MCT-10-0245.
[12] O’halloran TV, Ahn R, Hankins P, et al.The many spaces of uPAR:delivery of theranostic agents and nanobins to multiple tumor compartments through a single target[J].Theranostics, 2013, 3(7):496-506.DOI:10.7150/thno.4953.
[13] Su SC, Lin CW, Yang WE, et al.The urokinase-type plasminogen activator(uPA) system as a biomarkerand therapeutic target in human malignancies[J].Expert Opin Ther Targets, 2015, 19(12):1-16.DOI:10.1517/14728222.2016.1113260.
[14] Lin L, Gårdsvoll H, Huai Q, et al.Structure-based engineering of species selectivity in the interaction between urokinase and its receptor:implication for preclinical cancer therapy[J].J Biol Chem, 2010, 285(14):10982-10992.DOI:10.1074/jbc.M109.093492.
[15] Appella E, Robinson EA, Ullrich SJ, et al.The receptor-binding sequence of urokinase.A biological function for the growth-factor module of proteases[J].J Biol Chem, 1987, 262(10):4437-4440.
[16] Magdolen V, Bürgle M, De Prada NA, et al.Cyclo19, 31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor(CD87)[J].Biol Chem, 2001, 382(8):1197-1205.DOI:10.1515/BC.2001.150.
[17] Armstrong AF, Lemon JA, Czorny SK, et al.Evaluation of single amino acid chelate derivatives and regioselective radiolabelling of a cyclic peptide for the urokinase plasminogen activator receptor[J].Nucl Med Biol, 2009, 36(8):907-917.DOI:10.1016/j.nucmedbio.2009.07.001.
[18] Ploug M,?stergaard S, Gårdsvoll H, et al.Peptide-derived antagonists of the urokinase receptor.affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation[J].Biochemistry, 2001, 40(40):12157-12168.
[19] Kriegbaum MC, Persson M, Haldager L, et al.Rational targeting of the urokinase receptor(uPAR):development of antagonists and non-invasive imaging probes[J].Curr Drug Targets, 2011, 12(12):1711-1728.
[20] Liu D, Overbey D, Watkinson L, et al.Synthesis and characterization of an 111In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor(uPAR)[J].Bioconjug Chem, 2009, 20(5):888-894.DOI:10.1021/bc800433y.
[21] 孙芳芳, 冯洪波, 杨春, 等.99Tcm-AE105的制备及荷胰腺癌裸鼠显像研究[J].中华核医学与分子影像杂志, 2013, 33(6):483-488.DOI:10.3760/cma.j.issn.2095-2848.2013.06.019.Sun FF, Feng HB, Yang C, et al.Synthesis of 99Tcm-HYNIC-AE105 and its application for imaging urokinase plasminogen activator receptors in human pancreatic cancer xenografts by gamma imaging[J].Chin J Nucl Med Mol Imaging, 2013, 33(6):483-488.
[22] Duriseti S, Goetz DH, Hostetter DR, et al.Antagonistic anti-urokinase plasminogen activator receptor(uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration[J].J Biol Chem, 2010, 285(35):26878-26888.DOI:10.1074/jbc.M109.077677.
[23] Lebeau AM, Sevillano N, King ML, et al.Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance[J].Theranostics, 2014, 4(3):267-279.DOI:10.7150/thno.7323.
[24] Li ZB, Niu G, Wang H, et al.Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET[J].Clin Cancer Res, 2008, 14(15):4758-4766.DOI:10.1158/1078-0432.CCR-07-4434.
[25] Persson M, Madsen J,?stergaard S, et al.Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105:implications for visualizing cancer invasion[J].J Nucl Med, 2012, 53(1):138-145.DOI:10.2967/jnumed.110.083386.
[26] Boswell CA, Regino CA, Baidoo KE, et al.Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling[J].Bioconjug Chem, 2008, 19(7):1476-1484.DOI:10.1021/bc800039e.
[27] Persson M, Hosseini M, Madsen J, et al.Improved PET imaging of uPAR expression using new 64Cu-labeled cross-bridged peptide ligands:comparative in vitro and in vivo studies[J].Theranostics, 2013, 3(9):618-632.DOI:10.7150/thno.6810.
[28] Persson M, Madsen J,?stergaard S, et al.68Ga-labeling and in vivo evaluation of a uPAR binding DOTA-and NODAGA-conjugated peptide for PET imaging of invasive cancers[J].Nucl Med Biol, 2012, 39(4):560-569.DOI:10.1016/j.nucmedbio.2011.10.011.
[29] Persson M, Liu H, Madsen J, et al.First 18F-labeled ligand for PET imaging of uPAR:in vivo studies in human prostate cancer xenografts[J].Nucl Med Biol, 2013, 40(5):618-624.DOI:10.1016/j.nucmedbio.2013.03.001.
[30] Persson M, El Ali HH, Binderup T, et al.Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging[J].Nucl Med Biol, 2014, 41(3):290-295.DOI:10.1016/j.nucmedbio.2013.12.007.
[31] Persson M, Skovgaard D, Brandt-Larsen M, et al.First-in-human uPAR PET:Imaging of Cancer Aggressiveness[J].Theranostics, 2015, 5(12):1303-1316.DOI:10.7150/thno.12956.
[32] Dass K, Ahmad A, Azmi AS, et al.Evolving role of uPA/uPAR system in human cancers[J].Cancer Treat Rev, 2008, 34(2):122-136.
相似文献/References:
[1]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]安淑娴,宋少莉,黄钢.放射性核素标记的凋亡显像剂的研究进展[J].国际放射医学核医学杂志,2015,39(6):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
An Shuxian,Song Shaoli,Huang Gang.Recent advances in apoptosis imaging using radionuclide-labeled tracers[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
[5]黄建敏,解朋,刘晓梅,等.以整合素αvβ3为靶点的肿瘤分子显像及靶向治疗[J].国际放射医学核医学杂志,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
Huang Jianmin,Xie Peng,Liu Xiaomei,et al.Integrins αvβ3 in molecular imaging and targeted therapy of neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
[6]郭宵峰,刘建中,孙琦婷.肺通气/灌注平面显像与肺灌注SPECT/CT对肺栓塞诊断价值的对比性研究[J].国际放射医学核医学杂志,2015,39(4):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
Guo Xiaofeng,Liu Jianzhong,Sun Qiting.Comparative study of pulmonary ventilation/perfusion planar imaging and pulmonary perfusion SPECT combined with low-dose CT in the diagnosis of pulmonary embolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
[7]马春旭,袁卫红.甲状腺结节影像学诊断研究进展[J].国际放射医学核医学杂志,2014,38(1):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]
Ma Chunxu,Yuan Weihong.Advanced research on imaging diagnosis of thyroid nodule[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):48.[doi:10.3760/cma.j.issn 1673-4114.2014.01.010]
[8]吕靖,张一帆.核素分子显像监测胚胎干细胞及诱导性多潜能干细胞移植的研究进展[J].国际放射医学核医学杂志,2014,38(2):106.[doi:10.3760/cma.j.issn.1673-4114.2014.02.009]
Lyu Jing,Zhang Yifan.Advances in radionuclide imaging of monitoring embryonic stem cells and induced pluripotent stem cells transplantation[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):106.[doi:10.3760/cma.j.issn.1673-4114.2014.02.009]
[9]高平,王茜,赵赟赟,等.99Tcm-MDP SPECT/CT显像用于骨肉瘤肺转移的诊断[J].国际放射医学核医学杂志,2014,38(3):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
Gao Ping,Wang Qian,Zhao Yunyun,et al.99Tcm-MDP SPECT/CT used in diagnosis of pulmonary metastasis from osteosarcoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
[10]郝玉美,贺欣,宋娜玲.靶向肿瘤新生血管整合素αvβ3受体显像研究现状及进展[J].国际放射医学核医学杂志,2014,38(3):179.[doi:10.3760/cma.j.issn.1673-4114.2014.03.010]
Hao Yumei,He Xin,Song Naling.Progress on tumor angiogenesis imaging targeting integrin αvβ3 receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):179.[doi:10.3760/cma.j.issn.1673-4114.2014.03.010]